Servier receives NICE backing for colorectal cancer drug Lonsurf

Servier has received a recommendation from the National Institute for Health and Care Excellence (NICE) for its colorectal cancer drug Lonsurf to be made available through the NHS.

Final guidance from the UK regulator has backed the trifluridine/tipiracil therapy as a treatment for metastatic colorectal cancer in adults who have had previous treatment with available therapies.

This includes people who have failed to respond to fluoropyrimidine, oxaliplatin or irinotecan?based chemotherapies, anti?vascular endothelial growth factor agents and anti?epidermal growth factor receptor agents, or those for whom these treatments are not suitable.

Lonsurf is Servier UK's first oncology product and was approved by the European Commission earlier this year. The drug has been shown to extend the lives of cancer patients in clinical trials.

Since Lonsurf was included in the Cancer Drugs Fund, it will now be funded immediately, avoiding any delays in patients receiving the necessary treatment.

Dr Rob Glynne?Jones, consultant oncologist and Macmillan's lead clinician in gastrointestinal cancer at the Mount Vernon Cancer Centre, said: "Lonsurf is potentially a valuable new drug that I can offer to my patients with metastatic colorectal cancer regardless of their RAS status or resistance to previous lines of treatment."

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.